3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
33
Neoplasms
27
Colorectal Neoplasms
20
Breast Neoplasms
16
Ovarian Neoplasms
15
Pancreatic Neoplasms
13
Neoplasm Metastasis
12
Lung Neoplasms
11
Stomach Neoplasms
10
Leukemia, Myeloid, Acute
10
Melanoma
9
Lymphoma, Non-Hodgkin
8
Small Cell Lung Carcinoma
6
Recurrence
6
Liver Neoplasms
6
Leukemia
6
Head and Neck Neoplasms
6
Fallopian Tube Neoplasms
6
Prostatic Neoplasms
5
Glioblastoma
5
Cholangiocarcinoma
5
Adenocarcinoma
5
Urinary Bladder Neoplasms
4
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Sarcoma
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma
4
Gastrointestinal Neoplasms
4
Uterine Cervical Neoplasms
3
Interventions
belinostat
2
Gemcitabine
2
Fluorouracil
2
venetoclax
1
toripalimab
1
tazemetostat
1
resiquimod
1
poly ICLC
1
perifosine
1
pazopanib
1
ivosidenib
1
envafolimab
1
enasidenib
1
durvalumab
1
drozitumab
1
birinapant
1
Quality of Life
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Medicare Part B
1
Loperamide
1
Leucovorin
1
Irinotecan
1
Immunotherapy
1
Immune Checkpoint Inhibitors
1
Imatinib Mesylate
1
IPI-926
1
IFL protocol
1
Fentanyl
1
Drug Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Chondrosarcoma
×
Drug Therapy
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled